EML4-ALK rearrangement has been identified by the analysis of RNA platelets of NSCLC patients before starting treatment with an ALK-TKI and upon disease progression, reappearing even before positron emission tomography- computed tomography (PET-CT) will show disease progression [56]. This evidence concerns the gene ALK and non-small cell lung carcinoma.